Vistagen Reports Positive Results from P-IIa Study of PH15 for Improvement of Psychomotor Impairment
Shots:
- Vistagen reports P-IIa study (n=10) results, PH15 (1.6µg) shown statistically significant improvement in reaction time vs PBO & caffeine (p<0.001) in sleep-deprived participants at midnight and 3:00 a.m. (most fatigued) with no SAEs
- P-IIa study evaluating safety, efficacy & tolerability of intranasal PH15(1.6 µg multiple doses or 9.6 µg total dose) vs PBO (nasal spray or oral), or caffeine (single 400 mg oral dose 1 hr before session) in consecutive sleep deprivation sessions set apart 1wk, scheduled for 6:00 p.m., 9:00 p.m., midnight, and 3:00 a.m.
- Company to further explore PH15 as new and transformative solution for shift work disorder, sleep apnea, and narcolepsy (leads to debilitating sleep deprivation and mental fatigue)
Ref: Vistagen | Image: Vistagen
Related News:- Vistagen Reports P-III Trial (PALISADE-2) Results of Fasedienol (PH94B) Nasal Spray for Social Anxiety Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
